Spotlight on our research throughout 2023-2024.
Our Research Office has continued to be very busy throughout 2023- 2024. Of note was the completion and publication of the TAME and PATCH trials. Both of them were led by Alfred ICU Investigators, and published in the New England Journal of Medicine. These projects represent landmark trials in the fields of trauma and out-of-hospital cardiac arrest. We are currently involved in 30 different studies, all at various stages of completion.
TEAM was a NHMRC-funded Phase III, multicentre, multinational randomised controlled trial completed at 49 centres across 6 countries. It was established in 2017 to provide evidence for the provision of early mobilisation of critically ill, mechanically ventilated patients.
The TAME study is an Alfred investigator-led trial. It is the largest study undertaken in post-cardiac arrest ICU patients.
This Investigation studied whether prehospital administration of tranexamic acid increases the likelihood of survival with a favourable functional outcome among patients with major trauma and suspected trauma-induced coagulopathy who are being treated in advanced trauma systems.
REMAP-CAP is a randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia. The broad objective of this REMAP is, over time, to determine and continuously update the optimal set of treatments for community-acquired pneumonia.